Biopharma company signs deal with NRC in antibody development

Aurora, ON – Helix BioPharma says it has signed an agreement with the National Research Council of Canada’s Institute for Biological Sciences (NRC-IBS), to assist with the ongoing characterization of the lung cancer specific antibody previously licensed to Helix for its L-DOS47 new drug candidate; as well as to identify further novel tumor targeting antibodies.

“This joint effort by Helix and NRC-IBS is intended to contribute to the preclinical development program of L-DOS47 in support of Helix’s anticipated IND filing,” says Dr Heman Chao, Helix’s vice president of research.